Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Pharmigene, Inc.

Market Cap 414M 13.07M 11.4M 10.56M 9.88M 18.54M 1.23B 18.65M 125M 48.54M 607M 49.08M 48.02M 2.11B P/E 2024
-8.68x
P/E 2025 -6.84x
Enterprise Value 983M 31.07M 27.09M 25.09M 23.49M 44.05M 2.93B 44.31M 298M 115M 1.44B 117M 114M 5.01B EV / Sales 2024
10.1x
EV / Sales 2025 5.35x
Free-Float
49.29%
Yield 2024 *
-
Yield 2025 -
1 day+2.50%
1 week+0.74%
Current month-7.87%
1 month-17.26%
3 months-17.17%
6 months-17.26%
Current year-17.17%
1 week 7.75
Extreme 7.75
8.47
1 month 7
Extreme 7
9.54
Current year 7
Extreme 7
11.85
1 year 7
Extreme 7
14.1
3 years 7
Extreme 7
25.7
5 years 7
Extreme 7
25.7
10 years 7
Extreme 7
36
Manager TitleAgeSince
Chief Executive Officer 67 04/11/2019
Chief Operating Officer 49 04/11/2019
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 35 04/11/2019
Director/Board Member 65 07/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
+2.50%+0.74%-34.40%-63.88% 13.09M
+4.56%+13.31%+99.96%+105.56% 4.28B
+4.47%-0.40%+67.43%+108.94% 2.81B
+3.92%+3.83%-25.97%-38.60% 2.02B
-0.51%-4.17%+91.67%-51.85% 1.75B
+11.50%+13.97%+37.57%+228.89% 1.35B
-3.47%-0.89%-17.75%+17.55% 864M
-0.38%+4.42%+158.71%-62.26% 767M
-10.32%-23.08%+54.07% - 662M
-1.73%-5.87%-30.10%-17.39% 508M
Average +1.05%-0.68%+40.12%+25.22% 1.5B
Weighted average by Cap. +2.91%+2.67%+60.06%+59.66%

Financials

2024 2025
Net sales 117M 3.68M 3.21M 2.97M 2.78M 5.22M 347M 5.25M 35.27M 13.67M 171M 13.82M 13.52M 594M 200M 6.32M 5.51M 5.1M 4.77M 8.95M 596M 9.01M 60.5M 23.45M 293M 23.71M 23.2M 1.02B
Net income -82.86M -2.62M -2.28M -2.11M -1.98M -3.71M -247M -3.73M -25.08M -9.72M -122M -9.83M -9.62M -422M -73M -2.31M -2.01M -1.86M -1.74M -3.27M -218M -3.29M -22.09M -8.56M -107M -8.66M -8.47M -372M
Net Debt 458M 14.46M 12.61M 11.68M 10.93M 20.51M 1.36B 20.63M 139M 53.7M 672M 54.3M 53.13M 2.33B 570M 18M 15.69M 14.53M 13.6M 25.51M 1.7B 25.67M 172M 66.81M 836M 67.55M 66.1M 2.9B
Logo Pharmigene, Inc.
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
Employees
-
Date Price Change Volume
18/06/26 8.200 NT$ +2.50% 38,170
17/06/26 8.000 NT$ 0.00% 3,010
16/06/26 8.000 NT$ -1.84% 15,120
15/06/26 8.150 NT$ +0.12% 43,041
12/06/26 8.140 NT$ +0.62% 15,040
  1. Stock Market
  2. Stocks
  3. 7595 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!